AGEN - Agenus Inc.
2.5000 -0.04 (-1.57%)
After hours: 6:17PM EDT
| Previous Close | 2.6900 |
| Open | 2.6900 |
| Bid | 2.5300 x 4000 |
| Ask | 2.6000 x 36200 |
| Day's Range | 2.5300 - 2.7100 |
| 52 Week Range | 1.5400 - 3.8800 |
| Volume | 1,103,753 |
| Avg. Volume | 975,680 |
| Market Cap | 341.018M |
| Beta (3Y Monthly) | 1.70 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.7460 |
| Earnings Date | Jul 28, 2017 - Jul 31, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.50 |
- Zacks•7 days ago
Agenus (AGEN) Upgraded to Buy: What Does It Mean for the Stock?
Agenus (AGEN) has been upgraded to a Zacks Rank 2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
- Zacks•19 days ago
Gilead Inks Deal With Carna Biosciences for Immuno-Oncology
Gilead (GILD) teams up with Carna Biosciences to develop and commercialize small molecule compounds in immuno-oncology.
- Simply Wall St.•25 days ago
How Many Agenus Inc. (NASDAQ:AGEN) Shares Do Institutions Own?
If you want to know who really controls Agenus Inc. (NASDAQ:AGEN), then you'll have to look at the makeup of its share...
- Zacks•25 days ago
Gilead (GILD) Teams Up With Nurix for Cancer and Other Drugs
Gilead (GILD) collaborates with Nurix Therapeutics to leverage the proprietary drug discovery platform of the latter to identify novel agents that induce degradation of specified drug targets.
- PR Newswire•last month
Agenus to Host Annual Meeting of Stockholders
LEXINGTON, Mass. , June 13, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ...
- Thomson Reuters StreetEvents•last month
Edited Transcript of AGEN earnings conference call or presentation 9-May-19 12:30pm GMT
Q1 2019 Agenus Inc Earnings Call
- Zacks•last month
Why Is Agenus (AGEN) Down 6.3% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- PR Newswire•2 months ago
MiMedx Announces Comprehensive Board Refreshment Plan in Cooperation with Prescience Point
MARIETTA, Ga., May 30, 2019 /PRNewswire/ -- MiMedx Group, Inc. (OTC PINK: MDXG) ("MiMedx" or the "Company"), an industry leader in advanced wound care and an emerging therapeutic biologics company, today announced that the Company's board of directors (the "Board") has adopted a comprehensive plan to refresh the composition of the Board. The plan was developed by the Board in cooperation with one of the Company's largest shareholders, Prescience Point Capital Management LLC ("Prescience Point"), and follows the completion of the Audit Committee's independent investigation into alleged wrongdoing by the prior senior management team and the engagement of BDO USA, LLP as the Company's new independent registered public accounting firm.
- Zacks•2 months ago
Agenus' (AGEN) Pipeline Progression on Track Amid Competition
Agenus (AGEN) is developing its pipeline candidates and has an array of collaboration contracts to its credit that bodes well for growth.
- Zacks•2 months ago
Agenus (AGEN) Q1 Earnings Beat Estimates, Revenues Miss
Agenus' (AGEN) earnings beat estimates in the first quarter of 2019. Sales marginally miss the same.
Motley Fool•2 months agoAgenus Inc (AGEN) Q1 2019 Earnings Call Transcript
AGEN earnings call for the period ending March 31, 2019.
- Zacks•2 months ago
Agenus (AGEN) Surpasses Q1 Earnings Estimates
Agenus (AGEN) delivered earnings and revenue surprises of 140.00% and -4.65%, respectively, for the quarter ended March 2019. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•2 months ago
Agenus: 1Q Earnings Snapshot
The Lexington, Massachusetts-based company said it had net income of 12 cents per share. The biotechnology company posted revenue of $8.6 million in the period. The company's shares closed at $2.66. A ...
- PR Newswire•2 months ago
Agenus Reports First Quarter 2019 Financial Results and Provides Corporate Update
- Gilead partnership yields $150M & first milestone of $7.5M - Exceeding enrollment targets in BLA path CTLA-4 & PD-1 trials - Second generation CTLA-4 in the clinic; combos and data planned in 2019 - ...
- ACCESSWIRE•2 months ago
Agenus, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / May 9, 2019 / Agenus, Inc. (NASDAQ: AGEN ) will be discussing their earnings results in their 2019 First Quarter Earnings to be held on May 9, 2019 at 8:30 AM Eastern Time. ...
- PR Newswire•2 months ago
Agenus to Report First Quarter 2019 Financial Results on May 9, 2019 and Host Conference Call and Webcast
LEXINGTON, Mass. , May 3, 2019 /PRNewswire/ -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with a pipeline of immune modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies ...
- Simply Wall St.•3 months ago
Imagine Owning Agenus (NASDAQ:AGEN) And Wondering If The 41% Share Price Slide Is Justified
For many investors, the main point of stock picking is to generate higher returns than the overall market. But if you try your hand at stock picking, your risk returning less than the market. We regret to report that long ter...
- Zacks•3 months ago
Why Is Agenus (AGEN) Down 13% Since Last Earnings Report?
Agenus (AGEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
- Zacks•3 months ago
Gilead Files sNDA for Label Expansion of HIV Therapy Descovy
Gilead (GILD) submits sNDA to the FDA for label expansion of Descovy as PrEP to reduce the risk of sexually acquired HIV-1 infection.
- PR Newswire•3 months ago
Agenus Begins Dosing with Next-Gen Anti-CTLA-4 Antibody
LEXINGTON, Mass., April 2, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology company with a pipeline of immune-modulating antibodies, cancer vaccines, adjuvants and adoptive cell therapies1, today announced that the first patient was dosed in the clinical trial of its next-generation anti-CTLA-4 antibody (AGEN1181). AGEN1181, a novel 'Fc engineered' antibody with potential for enhanced anti-tumor functions, is specifically designed to boost cancer killing immune cells and deplete cells that block the activity of these cancer killing cells. The first patient in the trial was dosed by Dr. Steven J. O'Day, M.D., Executive Director of the John Wayne Cancer Institute & Cancer Clinic, and a pioneer in delivering immune therapies to patients with cancer. Dr. O'Day's pivotal work has led to the approvals of commercial antibodies targeting CTLA-4 and PD-1. "AGEN1181 represents an important next-generation breakthrough with its potential for enhanced immune activation and tumor fighting abilities," said Dr. O'Day.
- PR Newswire•4 months ago
Agenus Announces Clinical Appointments
LEXINGTON, Mass., March 21, 2019 /PRNewswire/ -- Agenus Inc. (AGEN), an immuno-oncology (I-O) company with a pipeline of immune checkpoint antibodies, cancer vaccines and adoptive cell therapies1, announced new leadership appointments as its CTLA-4 and PD-1 programs advance towards a planned BLA filing in 2020. Dr. Manuel Hidalgo, MD, PhD, joins as Strategic Advisor. Dr. Hidalgo, an internationally renowned oncologist, has led clinical development of more than 50 novel anticancer agents including erlotinib, temsirolimus and nab-paclitaxel, which are FDA approved for the treatment of cancer.
- Motley Fool•4 months ago
3 Top Growth Stocks to Buy Right Now
Surprise! This retailer and lesser-known biotechnology company could be potential multibaggers.
- Thomson Reuters StreetEvents•4 months ago
Edited Transcript of AGEN earnings conference call or presentation 14-Mar-19 12:30pm GMT
Q4 2018 Agenus Inc Earnings Call
- Zacks•4 months ago
Agenus Wins $7.5M Milestone Payment From Gilead, Stock Up
Agenus (AGEN) gets a $7.5-million milestone payment from Gilead following the FDA acceptance of the company's IND filing for AGEN1423. Shares rise.
Motley Fool•4 months agoAgenus Inc (AGEN) Q4 2018 Earnings Conference Call Transcript
AGEN earnings call for the period ending December 31, 2018.
